HC Wainwright Has Optimistic Outlook of EWTX Q3 Earnings

Posted by Francis Steltz on May 12th, 2026

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) – Equities researchers at HC Wainwright increased their Q3 2026 EPS estimates for Edgewise Therapeutics in a note issued to investors on Friday, May 8th. HC Wainwright analyst L. Egana-Gorrono now expects that the company will post earnings of ($0.50) per share for the quarter, up from their prior forecast of ($0.51). HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($2.15) per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q4 2026 earnings at ($0.59) EPS.

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.04.

Other analysts have also issued research reports about the stock. Stifel Nicolaus set a $25.00 price target on shares of Edgewise Therapeutics in a research note on Thursday, February 26th. Piper Sandler restated an “overweight” rating on shares of Edgewise Therapeutics in a research note on Monday, February 9th. Truist Financial set a $52.00 price target on shares of Edgewise Therapeutics in a research note on Wednesday, May 6th. Wedbush restated an “outperform” rating and issued a $32.00 price target on shares of Edgewise Therapeutics in a research note on Tuesday, March 17th. Finally, Evercore restated an “outperform” rating and issued a $45.00 price target on shares of Edgewise Therapeutics in a research note on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.67.

Read Our Latest Stock Report on Edgewise Therapeutics

Edgewise Therapeutics Trading Down 2.2%

Shares of NASDAQ:EWTX opened at $34.56 on Tuesday. The company has a fifty day simple moving average of $31.72 and a 200 day simple moving average of $27.09. The firm has a market cap of $3.71 billion, a PE ratio of -20.82 and a beta of 0.25. Edgewise Therapeutics has a 12-month low of $12.15 and a 12-month high of $39.96.

Insiders Place Their Bets

In other Edgewise Therapeutics news, CMO Joanne M. Donovan sold 50,000 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the sale, the chief marketing officer owned 4,367 shares in the company, valued at $168,435.19. The trade was a 91.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 83,892 shares of company stock worth $3,018,216 in the last three months. 23.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Edgewise Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Parallel Advisors LLC lifted its holdings in Edgewise Therapeutics by 64.9% in the first quarter. Parallel Advisors LLC now owns 1,032 shares of the company’s stock worth $33,000 after purchasing an additional 406 shares during the period. KBC Group NV acquired a new stake in Edgewise Therapeutics in the first quarter worth about $49,000. Seven Fleet Capital Management LP acquired a new stake in Edgewise Therapeutics in the fourth quarter worth about $50,000. Jones Financial Companies Lllp acquired a new stake in Edgewise Therapeutics in the first quarter worth about $47,000. Finally, Bessemer Group Inc. lifted its holdings in Edgewise Therapeutics by 1,170.3% in the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company’s stock worth $38,000 after purchasing an additional 2,165 shares during the period.

About Edgewise Therapeutics

(Get Free Report)

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.